Zoladex

DRUG20 trials

Conditions

Adenocarcinoma of the ProstateAdvanced Breast CancerAndrogen Deprivation TherapyBreast CancerCancer of ProstateEndometriosisHypogonadismInfertility

Phase 1

Effect of Increasing Testosterone on Insulin Sensitivity in Men With the Metabolic Syndrome

TerminatedNCT00438321

Massachusetts General HospitalMetabolic Syndrome

Start: 2006-09-30End: 2010-02-26Updated: 2017-04-18

Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer

NCT02626507

Hoffman OncologyBreast Cancer

Start: 2016-01-31End: 2022-03-15Target: 18Updated: 2022-02-09

A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer

CompletedNCT03450109

Luye Pharma Group Ltd.Cancer of Prostate

Start: 2017-12-22End: 2018-10-30Updated: 2019-01-07

A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male Participants

CompletedNCT07097259

EMD Serono Research & Development Institute, Inc.Hypogonadism

Start: 2025-07-21End: 2025-12-23Updated: 2026-02-24

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer

Not yet recruitingNCT07310420

TerSera Therapeutics LLCAdvanced Breast Cancer

Start: 2026-04-29End: 2027-03-30Target: 88Updated: 2026-03-11

Phase 2

Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment

CompletedNCT00165399

Dana-Farber Cancer InstituteAdenocarcinoma of the Prostate, Prostate Cancer

Start: 2004-03-31End: 2005-12-31Updated: 2018-06-25

Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer

CompletedNCT01250717

Beth Israel Deaconess Medical CenterProstate Cancer

Start: 2001-01-31End: 2011-05-31Updated: 2014-02-04

A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer

CompletedNCT02059213

University of Michigan Rogel Cancer CenterProstate Cancer

Start: 2014-06-30End: 2019-06-04Updated: 2020-09-16

Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/3 Trial

RecruitingCTIS2022-501551-90-00

Ziekenhuis Aan De StroomProstate cancer

Start: 2023-12-13Target: 583Updated: 2026-01-23

To Assess The Patient Preference for Goserelin Microsphere Versus Goserelin Implant in Patients With Prostate Cancer

RecruitingNCT06385847

The First Affiliated Hospital of Xiamen UniversityProstate Cancer

Start: 2024-05-31End: 2025-12-31Target: 60Updated: 2024-04-26

Phase 3

Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

CompletedNCT00002597

Radiation Therapy Oncology GroupProstate Cancer

Start: 1994-10-31End: 2018-05-14Updated: 2018-06-14

Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa in Treating ER+,Premenopausal Breast Cancer

CompletedNCT01712893

Fudan UniversityBreast Cancer

Start: 2009-06-30End: 2017-08-31Updated: 2017-08-25

Systemic Hormones and Muscle Protein Synthesis

NCT03054168

University of NottinghamMuscle Atrophy, Muscle Hypotrophy, Sarcopenia

Start: 2016-12-15End: 2019-02-15Updated: 2019-02-26

Phase 4

The Influence of Adjuvant Medical Treatment of Peritoneal Endometriosis on the Outcome of IVF. A Prospective Randomized Analysis.

CompletedNCT01682642

AZ Jan Palfijn GentEndometriosis, Infertility

Start: 2012-03-31End: 2014-10-31Updated: 2015-03-20

Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer

TerminatedNCT02749825

PharmatechProstate Cancer

Start: 2002-09-30End: 2006-07-31Updated: 2016-04-25

Fulvestrant in Metastatic Breast Cancer

NCT03591549

Assiut UniversityMetastatic Breast Cancer

Start: 2018-08-01End: 2021-10-01Target: 30Updated: 2018-07-23

Goserline Acetate VS Dienogest in Endometriosi

NCT05013242

Mansoura UniversityEndometriosis

Start: 2020-12-25End: 2021-12-25Target: 40Updated: 2021-10-20

Unknown Phase

A Prospective, Single-Arm Study to Evaluate the Efficacy and Safety of Zoladex 3.6mg Combined With CEF Chemotherapy as Neo-Adjuvant Therapy in Hormone Responsive, Premenopausal, Operable Breast Cancer

NCT00488722

Tianjin Medical UniversityBreast Cancer

Start: 2007-04-30End: 2009-03-31Updated: 2007-06-26

Androgen Deprivation Therapy Muscle Protein Metabolism and Blood Glucose

TerminatedNCT03440879

Norwegian School of Sport SciencesAndrogen Deprivation Therapy, Prostate Cancer, Resistance Exercise

Start: 2018-09-21End: 2023-03-02Updated: 2023-03-27

To Prevent Type I-II Myoma After TCRM Recurrence by Gonadotropin-releasing Hormone (GnRH )Analogues or Mifepristone

NCT05898321

Women's Hospital School Of Medicine Zhejiang UniversitySubmucous Leiomyoma of Uterus

Start: 2023-06-01End: 2025-12-30Target: 294Updated: 2023-06-12

NEJM Evidence2023-06-29101 citations

Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised Trial.

2023-01-285 citations

Clinical outcomes and markers of treatment response in a randomized phase II study of androgen deprivation therapy with or without palbociclib in RB-intact metastatic hormone-sensitive prostate cancer (mHSPC).

Journal of Clinical Oncology2020-05-207 citations

Cotargeting AR signaling and cell cycle: A randomized phase II study of androgen deprivation therapy with or without palbociclib in RB-positive metastatic hormone sensitive prostate cancer (mHSPC).

Journal of Clinical Oncology2018-02-205 citations

Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival.

2018-01-1322 citations

Feasibility of cotargeting cell cycle and androgen signaling in metastatic hormone-sensitive prostate cancer (mHSPC).

Journal of Clinical Oncology2017-02-20

Abstract IA06: Co-Targeting cell cycle and androgen signaling to personalize therapy for hormone dependent prostate cancer

Molecular Cancer Research2016-11-01

RCT to evaluate the influence of adjuvant medical treatment of peritoneal endometriosis on the outcome of IVF.

2016-07-0129 citations

A randomized phase II study of androgen deprivation therapy with or without PD0332991 in RB-positive metastatic hormone-sensitive prostate cancer.

Journal of Clinical Oncology2015-05-201 citations

Abstract P1-12-02: Effect of using LHRH analog during chemotherapy (CT) on premature ovarian failure and prognosis in premenopausal patients with early-stage, hormone receptor-positive breast cancer: The primary analysis of a randomized controlled phase III trial

Cancer Research2015-05-015 citations

Radiotherapy and short-term androgen deprivation for localized prostate cancer.

2011-07-01475 citations

A Phase II trial of Zoladex combined with CEF chemotherapy as neoadjuvant therapy in premenopausal women with hormone-responsive, operable breast cancer.

2011-03-063 citations